Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Treprostinil Palmitil Inhalation Powder, INS1009
Treprostinil Palmitil · 9 trials · 5 indications
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
Determination of the effect of mild, moderate, and severe hepatic impairment on the PK of TP and TRE following a single dose of TPIP, when compared to normal hepatic function.
| Arm | Type | Description |
|---|---|---|
| Treprostinil Palmitil Inhalation Powder (TPIP) | EXPERIMENTAL | Participants will receive TPIP, once daily (QD), at a starting dose of 80 micrograms (μg) to the maximum tolerated dose (up to 1280 μg) for up to 104 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a TPIP-matching placebo, QD for up to 104 weeks. |
| Treprostinil Palmitil Inhalation Powder | EXPERIMENTAL | Participants will receive TPIP, once daily (QD), at a starting dose of 80 micrograms (μg) up to maximum tolerated dose (up to 1280 μg) for 24 weeks. |
| Treprostinil Palmitil | EXPERIMENTAL | Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks. |
| Group 1: Treprostinil Palmitil Inhalation Powder | EXPERIMENTAL | Healthy participants with normal hepatic function will receive a single dose of TPIP on Day 1. |
| Group 2: Treprostinil Palmitil Inhalation Powder | EXPERIMENTAL | Participants with mild hepatic impairment (classified based on the numerical Child-Pugh total score of 5 to 6) will receive a single dose of TPIP on Day 1. |
| Group 3: Treprostinil Palmitil Inhalation Powder | EXPERIMENTAL | Participants with moderate hepatic impairment (classified based on the numerical Child-Pugh total score of 7 to 9) will receive a single dose of TPIP on Day 1. |
| Group 4: Treprostinil Palmitil Inhalation Powder | EXPERIMENTAL | Participants with severe hepatic impairment (classified based on the numerical Child-Pugh total score of 10 to 15) will receive a single dose of TPIP on Day 1. |
| Name | Type | Description |
|---|---|---|
| Treprostinil Palmitil Inhalation Powder | DRUG | Oral inhalation using a capsule-based dry powder inhaler device. |
| Placebo | DRUG | Oral inhalation using a capsule-based dry powder inhaler device. |
| Treprostinil Palmitil | DRUG | Administered by oral inhalation, using a Plastiape capsule-based dry powder inhaler. |
Inclusion Criteria: * Radiologic evidence of pulmonary fibrosis of \>10% extent on high-resolution computed tomography (HRCT) in the previous 12 months. * Diagnosis of interstitial lung disease (ILD) (other than idiopathic pulmonary fibrosis \[IPF\]) that fulfills at least 1 of the following criter...
Treprostinil Palmitil is an investigational small molecule developed by Insmed Incorporated as an inhalation powder. It is being studied in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, progressive pulmonary fibrosis, and hepatic impairment. It is also known as Treprostinil Palmitil Inhalation Powder, or TPIP.
Treprostinil Palmitil targets PTGIR, the prostacyclin receptor, and acts as an agonist at that receptor. Agonism of PTGIR is the mechanism attributed to the compound in its development as an inhaled small molecule for pulmonary vascular and fibrotic lung conditions.
Treprostinil Palmitil is developed by Insmed Incorporated, which trades under the ticker INSM. Insmed is the sponsor listed for the clinical trials of Treprostinil Palmitil Inhalation Powder, including the Phase 3 studies in pulmonary arterial hypertension and progressive pulmonary fibrosis.
Treprostinil Palmitil is investigational and has not been approved for any indication. It remains in clinical development, with Phase 3 trials recruiting in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and progressive pulmonary fibrosis, plus a Phase 1 pharmacokinetic study in hepatic impairment.
Treprostinil Palmitil is in four registered trials. NCT07481981 is a Phase 3 study in pulmonary arterial hypertension, NCT07805785 a Phase 3 study in progressive pulmonary fibrosis, and NCT07234032 a Phase 3 open-label extension in pulmonary hypertension with interstitial lung disease. NCT07643155 is a Phase 1 pharmacokinetic and safety study in hepatic impairment.
Yes. Treprostinil Palmitil Inhalation Powder, abbreviated TPIP, is the same investigational asset as Treprostinil Palmitil. The longer name describes the inhaled powder formulation used across the Insmed clinical program, and both names refer to the same PTGIR agonist compound.